You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: RE39820


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: RE39820
Title:Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Abstract:Compounds of the formula ##STR00001## of which, in exemplary compounds, the thienyl group is attached via the 2-position and; (a) A is 3.alpha.-(6.beta., 7.beta.-epoxy)-tropanyl methobromide and R.sub.1 is 2-thienyl; (b) A is 3.alpha.-(6, 7dehydro)-tropanyl methobromide and R.sub.1 is 2-thienyl; (c) A is 3.beta.-tropanyl methobromide and R.sub.1 is 2-thienyl; and, (d) A is 3.alpha.-(N-isopropyl)-nortropanyl methobromide and R.sub.1 is cyclopentyl. There are anticholinergics. Administered by inhalation, they are useful for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma. Administered by the intravenous or oral routes, they are useful for the treatment of vagally induced sinus bradycardia.
Inventor(s): Banholzer; Rolf (Stuttgart, DE), Bauer; Rudolf (Ockenheim, DE), Reichl; Richard (Gau-Algesheim, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:11/254,213
Patent Claims: 1. A compound of the formula ##STR00026## wherein Q is a group of the formula .[.--CH.sub.2--CH.sub.2--,.]. --CH.dbd.CH-- or ##STR00027## R and R' are each independently C.sub.1-C.sub.4-alkyl; R.sub.1 is thienyl, phenyl, cyclopentyl or cyclohexyl; and, X.sup.- is a physiologically acceptable anion.

2. A compound in accordance with claim 1, of the formula ##STR00028## wherein R is CH.sub.3, C.sub.2H.sub.5, n-C.sub.3H.sub.7, or i-C.sub.3H.sub.7; R' is CH.sub.3; and R.sub.1, Q and X.sup.- are as defined in claim 1.

3. A compound in accordance with claim 2 wherein R.sub.1 is thienyl.

4. A compound in accordance with claim 2 wherein X.sup.- is Br.sup.- or .[.CH.sub.3SO.sub.3.]. .Iadd.CH.sub.3SO.sub.3.sub.-.Iaddend..

5. A compound of the formula ##STR00029## wherein X.sup.- is a physiologically acceptable anion.

6. A compound of the formula ##STR00030## wherein X.sup.- is a physiologically acceptable onion.

7. A compound of the formula ##STR00031##

8. A compound of the formula ##STR00032## wherein R.sub.1 is 2-thienyl and A is 3.alpha.-(6,7-dehydro)-tropanyl methobromide.

.[.9. A compound of the formula ##STR00033## wherein R.sub.1 is 2-thienyl and A is 3.beta.-tropanyl methobromide..].

.[.10. A compound of the formula ##STR00034## wherein R.sub.1 is cyclopentyl and A is 3.alpha.-(N-isopropyl)-nortropanyl methobromide..].

11. A method for treating chronic obstructive bronchitis which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, .Iadd.or .Iaddend.8.[., 9, 10.]. .

.[.12. A method for treating slight to moderately severe asthma which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, 8, 9, 10..].

13. A method for treating vagally induced sinus bradycardia which comprises administering, by the intravenous or oral routes, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 1, 2, 3, 4, 6, 7, .Iadd.or .Iaddend.8.[., 9, 10.]. .

14. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis .[.or slight to moderately severe asthma.]. , which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, .Iadd.or .Iaddend.8.[., 9, 10.]. .

15. A pharmaceutical composition for oral administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, .Iadd.or .Iaddend.8.[., 9, 10.]. .

16. A pharmaceutical composition, for intravenous administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 1, 2, 3, 4, 6, 7, .Iadd.or .Iaddend.8.[., 9, 10.]. .

.Iadd.17. A method for treating chronic obstructive bronchitis which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claim 5..Iaddend.

.Iadd.18. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis, which comprises a compound in accordance with claim 5..Iaddend.

.Iadd.19. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis, comprising an inhalation powder comprising a compound in accordance with claim 5..Iaddend.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.